
Keywords: Liver cancer; Progenitor cells; Thalidomide; Analogues; Lenalidomide; Sorafenib; Apoptosis; Mitosis; LPCs; liver progenitor cells; HCC; hepatocellular carcinoma; FDA; Federal Drug Administration; SAR; structure activity relationship; BMOL; bipotential mou